• Investors
  • News
  • Careers
  • Contact
  • Global Need
    • Vaccines
    • History & Impact
  • Our Solution
    • Oral Vaccines
    • Technology
    • Vaccine Advantages
    • Platform Advantages
  • Pipeline
    • Research & Development
    • Norovirus
    • Influenza
    • RSV
    • HPV
  • About Us
    • Our Mission
    • Our Team
    • Careers
    • Contact
    • Compliance
  • Investors
  • News
  • Careers
  • Contact

Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.

Vaxart Provides Merger Update

Vaxart Announces Positive Results for its Oral Norovirus Vaccine in Phase 1b Clinical Study

Aviragen Therapeutics and Vaxart Enter into Merger Agreement

Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study

Vaxart to Present at the Jefferies 2017 Healthcare Conference

Vaxart to Present at Investor Conferences in March

Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine

Vaxart Initiates Clinical Development of First Oral Norovirus Vaccine

Vaxart Initiates Clinical Development of First Oral RSV Vaccine

Posts navigation

1 2 … 4 Next
Media Contacts

Katie Hogan, WCG
415.658.9745
khogan@wcgworld.com

Samir Singh, Vaxart
908.720.622,4
ssignh@vaxart.com

Get Updates

Subscribe to receive news alerts now.

© 2020 Vaxart, Inc., All rights reserved. Terms of UsePrivacy Policy